Catalyst Wire Dossier Catalyst Wire Dossier

Ulevostinag

MK-1454 · Merck Sharp & Dohme LLC
Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for Ulevostinag, covering 2023-10-27 to 2024-02-26. Get the full timeline:

Most recent: Clinical Trial Update: Study of Ulevostinag (MK-1454) Alone or in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001) [Phase 1]

See pricing